

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 283629US0PCT		SERIAL NO. 10/562,486	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Haruo SUGIYAMA			
				FILING DATE December 27, 2005		GROUP 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2007/0082860	04/12/2007	SUGIYAMA, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	03/106682	12/24/2003	WIPO (corresponds to US 2007/0082860)			
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AV	Akihiro TSUBOI, et al., "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", Cancer Immunol Immunother, (2002), Vol. 51 pages 614-620					
	AW	Yoshihiro OKA, et al., "Cancer Immunotherapy Targeting Wilms'Tumor Gene WT1 Product'", The Journal of Immunology, Vol. 164, pages 1873-1880					
	AX	Y. MAEDA, et al., "Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients", British Journal of Cancer, (2002) Vol. 87, pages 796-804					
	AY	Hideki OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8 ⁺ cytotoxic T-lymphocyte clone specific for WT1 peptide", Blood, January 1, 2002, Vol. 95, No. 1, pages 286-293					
	AZ	Akihiro TSUBOI, et al. "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", (1996), Vol. 274, pages 94-96, XP003016309, (CAPLUS-abstract)				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner							
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							